Additionally, another study by Al-Abady et al. (2024) highlights the combined role of LDH and caspase-3 as potential biomarkers for mediating CRC therapy, further supporting LDH’s role as an indicator of treatment response and disease progression [47,48]. Here, CASP3 is linked to colorectal carcinoma.